Xtrackers MSCI Global SDG 3 Good Health

ETF description

This ETF is designed to invest in companies that contribute to good health and well‑being, aligning with the United Nations' Sustainable Development Goals. It focuses on businesses involved in sectors such as healthcare, pharmaceuticals, biotechnology, and medical devices. By investing in this ETF, individuals gain exposure to a diverse range of companies that are working towards improving health outcomes and advancing medical innovation globally.

Investors who are passionate about health‑related initiatives and the positive impact of healthcare advancements may find this ETF appealing. It may attract those who wish to support companies that prioritize public health while potentially benefiting from the growth in the healthcare sector. The ETF aims to offer a balanced representation of various industries related to health, which helps to manage investment risk.

Issuer details

Xtrackers is a large and established provider of high quality ETFs and exchange traded commodities (ETCs). It is the ETF and ETC segment of the German asset manager DWS.

Xtrackers ETFs are listed on eleven stock exchanges globally and have over £169.53bn (as at June 2024) in assets under management, making Xtrackers one of the largest providers of ETFs and ETCs by AUM.

Index details

The MSCI ACWI IMI SDG 3 Good Health and Well‑being Select Index aims to reflect the performance of large, medium, and small‑capitalisation companies across developed and emerging markets globally; companies associated with a positive contribution to Sustainable Development Goal 3: ensure healthy lives and promote well‑being for all at all ages of the United Nations 2030 Agenda for Sustainable Development and which meet certain ESG criteria. To be eligible for inclusion securities must meet a certain threshold on the theme of digital healthcare and/or be part of the certain business segments including not limited to: (i) major disease treatment; (ii) sanitation; (iii) conventional pollution control solutions; and (iv) low toxicity and/or low volatile organic compounds solutions. The index is reviewed semi‑annually and rebalanced at least quarterly.